Medical technology company Brainlab has postponed its planned initial public offering (IPO) in Frankfurt due to investor withdrawals, according to sources familiar with the situation.

The Munich-based firm announced that it may consider an IPO at a later date but did not specify the reasons for the delay.

The offering was expected to raise €320 million (US$378 million) with shares priced at €80 (US$94.4) each.

Reports indicated that there was sufficient demand to cover the offering at the lower end of the marketed range.

However, some investors withdrew their orders on June 30, 2025 night, expressing concerns about potential stock performance post-trading.

🔗 Source: Bloomberg

🧠 Food for thought

1️⃣ European IPO window narrows amid broader market caution

Brainlab’s postponement reflects a pattern affecting the entire European IPO market, not just an isolated company issue.

As investment manager Michael Gierse noted, “IPOs are coming too late in the window and investors don’t want to take on risk before the summer holidays,” highlighting the critical importance of timing in public offerings.

The European IPO market faced significant challenges in 2025, with Reuters reporting a 64% decline to $5.8 billion compared to the previous year 1.

This slowdown follows Autodoc’s recent IPO delay for similar reasons, suggesting a systemic issue where investors are increasingly wary of post-IPO performance risks.

Multiple financial institutions have documented this trend, with Goldman Sachs noting that while European equity markets are technically “open,” issuers face heightened investor scrutiny before committing capital 2.

The trend shows how even well-established companies with three decades of operations like Brainlab must navigate increasingly narrow market windows.

2️⃣ Medical technology firms face unique IPO challenges despite sector growth

Brainlab’s postponement marks its second abandoned IPO attempt, having previously withdrawn during the 2001 dot-com crash, demonstrating the persistent challenges medical technology companies face despite their innovation.